Medxy AI

Rapid Remission and Low Disease Activity: Real-World Evidence for Anifrolumab in Systemic Lupus Erythematosus

By MedXY 02/17/2026

Interim data from the multicentre REVEAL study demonstrate that anifrolumab facilitates rapid disease control in real-world SLE patients, with 66% achieving low disease activity within six months, particularly in those with mucocutaneous and articular involvement.

Gastroenterology Internal Medicine news

Monthly Efimosfermin Alfa Demonstrates Safety and Tolerability in MASH-Related Fibrosis: Insights from a Phase 2 Trial

By MedXY 02/16/2026

The Phase 2 trial of efimosfermin alfa (BOS-580) shows that once-monthly dosing is safe and well-tolerated in patients with MASH and F2/F3 fibrosis, supporting its continued clinical development as a potential liver-targeted therapy.

Cardiology Internal Medicine news

Challenging the Label: Large-Scale Meta-Analysis Refutes Most Statin-Attributed Adverse Effects

By MedXY 02/16/2026

A comprehensive meta-analysis of double-blind RCTs by the CTT Collaboration reveals that the majority of adverse effects listed on statin labels, including cognitive and sleep issues, lack causal evidence, suggesting a need for urgent regulatory revisions.

Neurology news

Tenecteplase Improves 90-Day Functional Outcomes in Basilar Artery Occlusion Within a 24-Hour Window: Results from TRACE-5

By MedXY 02/16/2026

The TRACE-5 trial demonstrates that tenecteplase significantly improves functional outcomes for patients with basilar artery occlusion within 24 hours of onset, offering a safe and effective extension of the therapeutic window for this high-mortality condition.

Infectious Diseases news Public Health

Beyond Symptom Resolution: Physiological Recovery Lags Behind Subjective Wellness in COVID-19 and Influenza

By MedXY 02/16/2026

A 2-year prospective cohort study reveals that physiological recovery, measured via smartwatches, significantly lags behind self-reported symptom resolution, particularly in moderate-to-severe COVID-19 cases, suggesting a need for revised post-infection activity guidelines and precision monitoring.

HIV/AIDS Infectious Diseases news

Early Inpatient Initiation of 1-Month TB Preventive Therapy Proves Non-Inferior for Patients with Advanced HIV and Cryptococcal Meningitis

By MedXY 02/16/2026

The IMPROVE trial demonstrates that starting a one-month isoniazid-rifapentine (1HP) course during hospitalization for cryptococcal meningitis is as safe and effective as outpatient initiation, potentially increasing treatment completion rates in high-risk patients with advanced HIV.

General Surgery news Oncology

Systematic Complication Management Boosts Long-Term Survival in Pancreatic Cancer: Insights from the PORSCH Trial

By MedXY 02/16/2026

A post-hoc analysis of the nationwide PORSCH trial reveals that algorithm-based care for early recognition and management of postoperative complications significantly improves long-term overall survival in patients undergoing pancreatic resection for cancer, particularly those with pancreatic ductal adenocarcinoma.

news Orthopedics Pediatrics

Surgical Fixation Offers No Clinical Benefit and Zero Cost-Effectiveness for Pediatric Medial Epicondyle Fractures: Results from the SCIENCE Trial

By MedXY 02/16/2026

The SCIENCE multicentre randomized trial demonstrates that surgical fixation for displaced medial epicondyle fractures in children provides no functional advantage over non-surgical care, carries higher complication risks, and is not a cost-effective use of healthcare resources.

Nephrology news

Selective TRPC6 Inhibition Emerges as a Novel Therapeutic Paradigm for Focal Segmental Glomerulosclerosis

By MedXY 02/16/2026

A Phase 2 trial of BI 764198, a selective TRPC6 inhibitor, demonstrates significant proteinuria reduction in patients with focal segmental glomerulosclerosis. This study provides the first clinical evidence for podocyte-targeted therapy, marking a potential shift in the management of progressive proteinuric kidney diseases.

HIV/AIDS Infectious Diseases news

Doravirine and Islatravir Combination Proves Non-Inferior to B/F/TAF: A New Era for Two-Drug HIV Maintenance

By MedXY 02/15/2026

Phase 3 trial results demonstrate that a daily fixed-dose combination of doravirine and islatravir effectively maintains virological suppression in adults with HIV-1, offering a comparable and safe alternative to standard integrase inhibitor-based regimens.

Internal Medicine Neurology news

Delirium as a Sentinel Event: New UK Biobank Data Links Acute Brain Failure to Decades of Multisystem Vulnerability

By MedXY 02/15/2026

A large-scale matched cohort study from the UK Biobank identifies in-hospital delirium as a sentinel marker for long-term multisystem vulnerability. Associated with increased risks of sepsis, AKI, and falls, delirium signals a profound physiological decline that persists independently of pre-existing frailty or dementia.

Infectious Diseases news Public Health

Obesity Linked to Three-Fold Increase in Severe Infection Risk: A Global Analysis of 925 Pathogens

By MedXY 02/15/2026

A large-scale multicohort study reveals that adult obesity significantly increases the risk of hospitalization and death across nearly 1,000 infectious diseases, accounting for approximately one in ten infection-related deaths globally.

Infectious Diseases news Rheumatology

Recombinant Herpes Zoster Vaccine Demonstrates Safety and Non-Inferiority in Patients with Autoimmune Rheumatic Diseases

By MedXY 02/15/2026

A phase 4 RCT in Brazil confirms that the recombinant zoster vaccine does not increase the risk of disease flares in patients with autoimmune rheumatic diseases compared to placebo, maintaining a favorable safety profile even under immunosuppressive therapy.

HIV/AIDS news OB/GYN & Women’s Health

Dapivirine Vaginal Ring and Oral PrEP Confirmed Safe for Use During Second Trimester: Insights from the DELIVER Trial

By MedXY 02/14/2026

The Phase 3b DELIVER trial confirms that both the dapivirine vaginal ring and oral PrEP are safe and well-tolerated when initiated in the second trimester of pregnancy, showing no product-related serious adverse events and high rates of term births.

Hematology-Oncology news Oncology

Beyond Standard Staging: A Novel Genetics-Based Model Refines Prognosis for AML Patients Treated with Venetoclax and Hypomethylating Agents

By MedXY 02/14/2026

A newly developed prognostic model integrates mutational and cytogenetic data to accurately predict survival in AML patients receiving HMA/VEN therapy, offering superior risk stratification into low-, intermediate-, and high-risk categories with distinct survival durations.

HIV/AIDS news Pediatrics

Dolutegravir and Metabolic Health in Children: Five-Year Insights from the ODYSSEY Trial

By MedXY 02/14/2026

Ancillary analysis of the ODYSSEY trial demonstrates that dolutegravir-based ART is not associated with excessive weight gain or adiposity in children and adolescents compared to standard care, while offering a superior metabolic profile over five years of follow-up.

Allergy & Immunology news Pediatrics

Paracetamol vs. Ibuprofen in Infancy: The PIPPA Tamariki Trial Finds No Differential Risk for Eczema or Bronchiolitis

By MedXY 02/14/2026

The PIPPA Tamariki randomized controlled trial demonstrates that using paracetamol versus ibuprofen as needed in the first year of life does not significantly alter the risk of developing eczema or bronchiolitis by age one, challenging long-standing concerns from observational studies.

news Pediatrics Public Health

The Global Crisis of Paediatric Suffering: 81% of Palliative Care Needs Now Stem from Survivors, Not Decedents

By MedXY 02/14/2026

A 30-year analysis reveals that 10.6 million children experience serious health-related suffering annually, with a massive shift toward chronic, non-decedent care needs in low- and middle-income countries.

Critical Care news Pediatrics

Automated Oxygen Control vs. Manual Care: Large-Scale Trial Finds No Difference in Clinical Outcomes for Extremely Preterm Infants

By MedXY 02/14/2026

A multicenter randomized trial of 1,082 extremely preterm infants found that automated FiO2 control did not significantly reduce death or major morbidities compared to manual titration, though it remains a safe labor-saving tool for neonatal intensive care units.

news OB/GYN & Women’s Health Public Health

Early Pregnancy Matters: PM2.5 Exposure Linked to Reduced Birth Weight in Large-Scale ECHO Cohort

By MedXY 02/14/2026

A retrospective analysis of the ECHO cohort reveals that prenatal exposure to fine particulate matter (PM2.5) is associated with lower birth weight for gestational age, with critical windows of susceptibility identified as early as the first five weeks of pregnancy.